TMCnet News
Sun BioPharma, Inc. Announces Appointment of Susan Horvath as Vice President of Finance and Chief Financial OfficerMINNEAPOLIS, April 16, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today announced the appointment of Susan Horvath as Vice President of Finance and Chief Financial Officer, effective April 17, 2018. “We are very pleased to welcome Susan to Sun BioPharma’s executive team”, said David B. Kaysen, President and CEO. “Susan brings an outstanding balance of experience in public and private enterprises in several different industries. She has proven to be a strong financial and strategic partner within her previous organizations with broad industry and international experience.” Ms. Horvath is a highly qualified senior executive. She has held both finance and operating positions within pharmaceutical, healthcare and consumer organizations, most recently as Chief Financial Officer of eyebobs, LLC. She is a Certified Public Accountant (inactive), and a Certified Management Accountant and graduated with highest honors with a Bachelor of Science in Accounting from the University of Illinois. “I am very excited to be joining Sun BioPharma at this stage of the company’s development”, said Ms. Horvath. “I look forward to assisting this outstanding team as we focus on our clinical pathway and continue to evolve our corporate strategy to advance SBP-101 for the treatment of patients with pancreatic cancer.” Ms. Horvath is replacing Scott Kellen who was Vice President of Finance and Chief Financial Officer from October 201 until April 2018. “We all wish Scott nothing but the best in his new position. Scott has been an integral part of Sun BioPharma, setting a strong public company foundation with appropriate systems and controls that will serve us well into the future”, said David B. Kaysen. Michael T. Cullen, M.D., MBA, Founder and Executive Chairman said, “All of us at Sun BioPharma look forward to welcoming and working with Susan as we continue to grow as an organization. It is with gratitude and respect that we send our best wishes with Scott as he moves on to a new opportunity.” About SBP-101 About Sun BioPharma
Contact Information: Investor & Media Contact: Tammy Groene – Sun BioPharma, Inc. 952 479 1196 |